Raymond James Initiates Coverage On Spyre Therapeutics with Strong Buy Rating, Announces Price Target of $80

Benzinga Newsdesk www.benzinga.com Positive 89.6%

Neg 0% Neu 0% Pos 89.6%

Raymond James analyst Martin Auster initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Strong Buy rating and announces Price Target of $80.